IsoPlexis’ Mouse and Human Adaptive Immune Chips Advance Preclinical Research in Infectious Disease and Cancer

IsoPlexis received support from the Office of Research Infrastructure Programs (ORIP) for their phase I and phase II SBIR grant. The phase II grant (R44OD021445) entitled “A single-cell proteomic system to accelerate pre-clinical immune therapeutics” was completed in December 2021. The funding has led to the development of mouse and human adaptive immune chips. We tested the 29-plex proteomic analysis platform for assaying mouse T-cells in collaboration with multiple academic researchers across areas of interest from cancer to infectious diseases. In addition, we demonstrated that our human T cell panel provides valuable data in humanized immune system mouse models, helping facilitate preclinical to clinical transitions for new immunotherapies.

In conclusion of this SBIR project, we demonstrated the value of the IsoPlexis single-cell proteomic platform by validating it in multiple mouse model studies. These studies ranged in topic from infectious disease such as Chikungunya and Malaria, to investigating tumor-infiltrating lymphocytes in lung cancers and blood cancer cells from bone marrow. Continuing this work, IsoPlexis’ platform has been used for testing of novel CAR-T therapies, radiation therapies, and immunotherapies, helping to advance preclinical research.

Share This Article
Subscribe to Follow the Data

Weekly email to keep you at the forefront of single-cell & multiplexed proteomics.